FLT3 (CD135) is a class III receptor tyrosine kinase expressed on hematopoietic stem and progenitor cells; activating FLT3 mutations are common in AML. FLT3 is a clinically validated AML target for TKIs and immunotherapy.
| Catalog No. | Product Name | Conjugate | Size | Price (In USD) |
|---|---|---|---|---|
| GM-Tg-hg-T74312-Ab-3-PE | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(PE) | PE | 25T | |
| GM-Tg-hg-T74312-Ab-3-PE | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(PE) | PE | 100T | |
| GM-Tg-hg-T74312-Ab-3-PE | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(PE) | PE | 500T | |
| GM-Tg-hg-T74312-Ab-3-FITC | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(FITC) | FITC | 25T | |
| GM-Tg-hg-T74312-Ab-3-FITC | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(FITC) | FITC | 100T | |
| GM-Tg-hg-T74312-Ab-3-FITC | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(FITC) | FITC | 500T | |
| GM-Tg-hg-T74312-Ab-3-APC | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(APC) | APC | 25T | |
| GM-Tg-hg-T74312-Ab-3-APC | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(APC) | APC | 100T | |
| GM-Tg-hg-T74312-Ab-3-APC | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(APC) | APC | 500T | |
| GM-Tg-hg-T74312-Ab-3-Biotin | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(Biotin) | Biotin | 25T, 100T, 500T |
| Target | FLT3 (specific biomarker for human hematopoietic progenitor / AML blast) |
|---|---|
| Species | Humanized |
| Expression platform | Mammalian cell |
| Isotypes | Human IgG |
| Tag | hFc |
| Conjugate | PE / FITC / APC / Biotin |
| Size | 25T / 100T / 500T |
| Purity | >=95% (SDS-PAGE) |
| Bioactivity validation | FLT3 binding, FACS in FLT3 level test |
| Application | FACS and other Immunoassay for FLT3 test |
| Products description | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) is a recombinant monoclonal antibody. It specifically recognizes FLT3 (Fms-like tyrosine kinase 3, expressed on hematopoietic progenitors and AML blasts). FLT3 is a hematopoietic progenitor / AML blast marker. This antibody is validated by FACS for AML target assessment. It is recommended for multi-color flow cytometry panels to validate FLT3 expression for AML-directed CAR-T target screening in CAR-T cell therapy manufacturing, QC and functional assessment. |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |